Science Current Events | Science News | Brightsurf.com
 

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012
CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research


Related Bevacizumab Current Events and Bevacizumab News Articles


Adding cediranib to chemo improves progression-free survival for meta or recurrent cervical cancer
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

Cancer-fighting cocktail demonstrates promising results as new treatment for advanced cervical cancer
Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

Cheaper alternative to licensed drug for treating eye disease has similar side-effects
Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today.

Women & Infants Breast Cancer Specialist Reports Advance in Treatment of Triple-Negative Breast Cancer
William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women.

Hijacking the brain's blood supply: Tumor discovery could aid treatment
Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time.

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Improved survival with TAS-102 in mets colorectal cancer refractory to standard therapies
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Researcher discovers ovarian cancer treatment
Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

Clinical trial shows drug combination may be effective in recurrent ovarian cancer
Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today.

Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.
More Bevacizumab Current Events and Bevacizumab News Articles

Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer

Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer
by Thomas Seyfried (Author)


The book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due...

Principles and Practice of Gynecologic Oncology

Principles and Practice of Gynecologic Oncology
by Richard Barakat FACS (Author), Andrew Berchuck (Author), Maurie Markman MD (Author), Marcus E. Randall MD FACR (Author)


Today, multidisciplinary approaches to treatment are at the heart of cancer care. They offer improved clinical outcomes, new possibilities in patient quality of life, and enable the development of true innovation in individualized treatment. To accurately reflect this modern day approach to cancer care, the content of the 6th edition of Principles and Practice of Gynecologic Oncology was written entirelyby surgeons, medical oncologists, radiation oncologists, and pathologists. New to the editorial team, Dr. Andrew Berchuck has made significant contributions to the understanding of the molecular pathogenesis of ovarian and endometrial cancer in the book’s content. Every chapter of this book has been either completely rewritten or extensively updated to ensure that everyone involved in...

Clinical Gynecologic Oncology: Expert Consult - Online and Print, 8e

Clinical Gynecologic Oncology: Expert Consult - Online and Print, 8e
by Philip J. DiSaia MD (Author), William T. Creasman MD (Author)


Clinical Gynecologic Oncology, by Drs. Di Saia and Creasman, is the leading medical reference book geared toward helping you improve gynecologic cancer outcomes. You'll see how to take advantage of the latest advances in early detection and improved treatment options for gynecologic cancers, especially uterine and cervical cancers, equipping you with the skills you need to provide effective and compassionate care for your patients.Easily identify and absorb key information with outlines beginning each chapter. Choose the best management plan for each patient using algorithms throughout the book. Stay at the forefront of your field thanks to new chapters on Genetic Counseling and Clinical Management of Inherited Disease; Molecular Genetics; and Minimally Invasive Surgery, plus sweeping...

Oncology Boards Flash Review

Oncology Boards Flash Review
by Francis P. Worden MD (Author), Rami N. Khoriaty MD (Author)


Oncology Boards Flash Review is a question-and-answer book designed to summarize the most important facts one needs to know for the medical oncology boards, including the most up-to-date information on well-established chemotherapy regimens for a variety of malignancies. Coverage extends across the range of major hematologic malignancies and solid tumors, and includes reviews of pharmacology, biostatistics, genetics and tumor biology, and survivorship and palliative care. The book covers all of the topics listed by the American Board of Internal Medicine as essential material for the Medical Oncology Board Examination. Each chapter is written by a fellow and edited by expert faculty and clinicians, and Flash Review includes key points summarized in bullet point form for easy recall....

Bevacizumab: Webster's Timeline History, 2001 - 2007

Bevacizumab: Webster's Timeline History, 2001 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Bevacizumab," including when used in literature (e.g. all authors that might have Bevacizumab in their name). As such, this book represents the largest compilation of timeline events associated with Bevacizumab when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

  Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article): An article from: Family Practice News
by Jeff Evans (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on September 1, 2003. The length of the article is 1131 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article)
Author: Jeff Evans
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2003
Publisher: International Medical News Group
Volume: 33 Issue: 17 Page: 42(1)

Article Type: Brief Article

Distributed by Thomson...

  Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds): An article from: Internal Medicine News
by Jeff Evans (Author)


This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2003. The length of the article is 318 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds)
Author: Jeff Evans
Publication: Internal Medicine News (Magazine/Journal)
Date: October 1, 2003
Publisher: International Medical News Group
Volume: 36 Issue: 19 Page: 26(1)

Distributed by Thomson...

  Bevacizumab improves survival in patients with colorectal cancer.(Gastroenterology): An article from: Internal Medicine News
by International Medical News Group (Publisher)


This digital document is an article from Internal Medicine News, published by International Medical News Group on April 1, 2005. The length of the article is 530 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab improves survival in patients with colorectal cancer.(Gastroenterology)
Publication: Internal Medicine News (Magazine/Journal)
Date: April 1, 2005
Publisher: International Medical News Group
Volume: 38 Issue: 7 Page: 69(1)

Distributed by Thomson...

  Bevacizumab aids survival in breast, lung, colorectal cancer: antiangiogenesis agent appears effective.(News): An article from: Family Practice News
by Jane Salodof MacNeil (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on June 15, 2005. The length of the article is 1884 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab aids survival in breast, lung, colorectal cancer: antiangiogenesis agent appears effective.(News)
Author: Jane Salodof MacNeil
Publication: Family Practice News (Magazine/Journal)
Date: June 15, 2005
Publisher: International Medical News Group
Volume: 35 Issue: 12 Page: 1(2)

Distributed by Thomson...

  Bevacizumab improved survival in leading cancers.(Clinical Rounds): An article from: Skin & Allergy News
by Jane Salodof MacNeil (Author)


This digital document is an article from Skin & Allergy News, published by International Medical News Group on July 1, 2005. The length of the article is 1396 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab improved survival in leading cancers.(Clinical Rounds)
Author: Jane Salodof MacNeil
Publication: Skin & Allergy News (Magazine/Journal)
Date: July 1, 2005
Publisher: International Medical News Group
Volume: 36 Issue: 7 Page: 60(1)

Distributed by Thomson...

© 2014 BrightSurf.com